Page:United States Statutes at Large Volume 108 Part 3.djvu/241

 PUBLIC LAW 103-g22-€EPT, 13, 19S4 1085TAT.1993 actually used, including data on intravenous drug users and pregnant women; "(ii) the extent, within each State, to which treatment is available, on demand, to intravenous drug users and pregnant women; "(iii) the number of drug users the Director estimates could benefit from treatment; and "(iv) the success of drug treatment programs, including an assessment of the effectiveness of the mechanisms in place federally, and within each State, to determine the relative quality of substance abuse treatment programs, the qualifications of treatment personnel, and the mechanism by which patients are admitted to the most appropriate and cost effective treatment setting. "(5) The Director shall include with the National Drug Control Strategy required to be submitted not later than February 1, 1995, and with every second such strategy submitted thereafter— "(A) an assessment of the quality of current drug use measurement instruments and techniques to measure supply reduction and demand reduction activities; "(B) an assessment of the adequacy of the coverage of existing national drug use measurement instruments and techniques to measure the casual drug user population and groups at-risk for drug use; "(C) an assessment of the actions the Director shall take to correct any deficiencies and limitations identified pursuant to subparagraphs (A) and (B); and "(D) identification of the specific factors that restrict the availability of treatment services to those seeking it and proposed administrative or legislative remedies to make treatment available to those individuals. "(6) Federal agencies responsible for the collection or estimation of drug-related information required by the Director shall cooperate with the Director, to the fullest extent possible, to enable the Director to satisfy the requirements of sections 4and5. "(7) With each National Drug Control Strategy, the Director shall report to the President and the Congress on the Director's assessment of drug use and availability in the United States, including an estimate of the effectiveness of interdiction, treatment, prevention, law enforcement, and international programs under the National Drug Control Strategy in effect in the preceding year in reducing drug use and availability.", SEC. 90204. COUNTER-DRUG TECHNOLOGY ASSESSMENT CENTER (a) DRUG ABUSE ADDICTION AND REHABILITATION CENTER. — Section 1003A of the National Narcotics Leadership Act of 1988 (21 U.S.C. 1502a(c)(l)) is amended— (1) by redesignating subparagraphs (B), (C), and (D) as subparagraphs (C), (D), and (E), respectively; and (2) by inserting after subparagraph (A) the following: "(B) in consultation with the National Institute on Drug Abuse, and through interagency agreements or grants, examine addiction and rehabilitation research and

�